b
r
c
macromolecular
pro
drug
hold
much
promis
broadspectrum
antivir
agent
either
microbicid
carrier
intracellular
deliveri
antivir
drug
intrigu
opportun
exist
combin
two
mode
antivir
activ
polym
structur
polym
act
microbicid
also
serv
deliv
conjug
drug
ribavirin
cell
explor
opportun
detail
focu
polym
backbon
decis
constitu
formul
fourteen
polyanion
polycarboxyl
polyphosph
polyphosphon
polysulfon
analyz
blood
proanti
coagul
effect
albumin
bind
albumin
aggreg
inhibitori
activ
polymeras
cytotox
antiinflammatori
activ
stimul
macrophag
ribavirin
contain
monom
design
accommod
synthesi
macromolecular
prodrug
disulfideexchang
trigger
drug
releas
kinet
drug
releas
fast
case
howev
enhanc
hydrophob
polym
significantli
slow
releas
ribavirin
result
studi
present
comprehens
view
polyanion
backbon
macromolecular
prodrug
ribavirin
broadspectrum
antivir
agent
virus
fascin
product
evolut
lifethreaten
pathogen
time
inde
noncellular
assembl
macromolecul
lipid
simpler
even
minimalist
replic
cell
infect
live
organ
plant
anim
kingdom
throughout
histori
viral
infect
repeatedli
devast
effect
human
societi
even
modern
time
viral
outbreak
creat
enorm
socioeconom
burden
recent
exampl
includ
outbreak
coronavirusassoci
southeast
asian
middl
eastern
respiratori
syndrom
sar
mer
well
ebola
zika
viru
outbreak
counter
interdisciplinari
effort
made
past
decad
design
develop
antivir
drug
larg
part
spur
spread
human
immunodefici
viru
hiv
current
nearli
one
hundr
antivir
drug
approv
us
fda
nevertheless
signific
challeng
remain
understood
signific
limit
current
strategi
countermeasur
viral
pathogen
typic
develop
individu
specif
emerg
pathogen
aspect
came
focu
research
attent
develop
broadspectrum
antivir
agent
agent
constitut
prophylact
prevent
cur
measur
prophylaxi
vaccin
hold
great
appeal
univers
antivir
vaccin
yet
develop
fact
overal
major
pathogen
virus
correspond
vaccin
product
turn
cur
measur
highli
attract
right
howev
replic
cycl
virus
similar
great
variabl
viral
enzym
protein
could
serv
drug
targetsmak
design
univers
antivir
agent
challeng
interferon
endogen
protein
serv
potent
stimulatori
signal
human
immun
act
nonspecif
broadli
act
antivir
agent
howev
virus
develop
multipl
interferon
inhibitor
compromis
induct
activ
interferon
moreov
due
side
effect
clinic
use
limit
sever
small
molecul
drug
also
serv
broadli
act
antivir
ribavirin
rbv
long
histori
medicin
use
appear
world
health
organ
list
essenti
medicin
adult
children
howev
drug
also
dose
limit
toxic
sever
experiment
drug
lead
differ
stage
pre
clinic
develop
final
prevent
antivir
act
neutral
virus
andor
block
viru
cell
entri
appear
highli
promis
broadspectrum
antivir
agent
notabl
class
agent
polym
earli
first
observ
virus
interact
polym
inhibit
viru
infect
subsequ
decad
effect
shown
affect
viral
pathogen
across
viral
genu
famili
observ
polym
divers
structur
natur
synthet
posit
neg
charg
de
clercq
et
al
propos
activ
neg
charg
polym
least
vivo
indirect
proce
via
stimul
interferon
product
howev
antivir
activ
proce
potent
efficaci
vitro
absenc
interferon
direct
contact
polym
viru
ensu
neutral
activ
welldocu
inher
skeptic
toward
polyanion
polym
antivir
origin
failur
hallmark
clinic
trial
agent
administ
system
topic
microbicid
specif
system
administr
conclud
prevent
antivir
effect
would
reli
sustain
high
concentr
agent
blood
achiev
without
toxic
effect
howev
polym
success
commerci
antivir
specif
lubric
condom
act
microbicid
activ
hiv
herp
simplex
virus
nucleic
acid
base
polyanion
progress
clinic
trial
agent
hepat
b
viru
potenti
develop
broadspectrum
antivir
activ
import
note
fail
clinic
trial
inde
discourag
yet
import
gamechang
develop
occur
polym
chemistri
recent
decad
specif
novel
polymer
techniqu
avail
afford
polym
wellcontrol
molar
mass
architectur
significantli
broader
avail
polym
function
side
chain
anoth
notabl
advanc
includ
develop
polymer
virucid
agent
compromis
stabil
viral
envelop
exert
perman
damag
virion
togeth
broad
spectrum
activ
polym
viral
pathogen
chemic
versatil
agent
render
class
antivir
agent
uniqu
attract
deeper
investig
past
studi
develop
broadspectrum
antivir
agent
base
macromolecular
prodrug
mp
ribavirin
conjug
polym
ribavirin
accumul
red
blood
cell
vivo
main
side
effect
drug
mp
ribavirin
broaden
therapeut
window
drug
vitro
effect
divers
virus
hcv
replicon
cell
cultur
model
measl
influenza
latter
case
reveal
antivir
effect
chicken
embryo
model
also
experiment
confirm
link
ribavirin
synthesi
nitric
oxid
macrophag
relev
treatment
hepat
key
success
deliveri
ribavirin
use
mp
develop
disulfidecontain
linker
releas
drug
prodrug
upon
cell
entri
differ
perspect
also
focus
prevent
measur
conduct
systemat
studi
polym
anion
charg
inhibitor
viru
cell
entri
broad
studi
consid
polym
infecti
zika
viru
hiv
hsv
well
pseudotyp
viral
particl
ebola
lassa
lyssa
sar
virus
main
find
work
anion
charg
alon
carboxyl
phosphatephosphon
sulfon
endow
polym
broadspectrum
antivir
activ
decis
factor
activ
enhanc
balanc
hydrophob
macromolecul
identifi
lead
candid
polym
exhibit
antivir
activ
envelop
viral
pathogen
includ
zika
viru
latter
present
evid
direct
contact
polym
viral
particl
concurr
inhibit
viral
infect
one
intrigu
possibl
lie
prospect
combin
cur
prevent
antivir
activ
within
macromolecular
antivir
agent
agent
repres
combin
therapi
wherein
carrier
exert
extracellular
prevent
effect
wherea
conjug
drug
releas
insid
cell
intracellularli
activ
therapeut
also
possibl
polyanion
intracellular
antivir
effect
inhibit
viral
polymeras
presum
competit
electrostat
interact
protein
work
explor
design
combin
therapi
detail
focu
choic
macromolecular
backbon
carrier
conjug
drug
analyz
blood
coagul
bind
albumin
albumin
aggreg
inhibitori
activ
polymeras
cytotox
polym
differ
anion
charg
carboxyl
phosphat
phosphon
sulfon
synthes
ribavirincontain
counterpart
polyanion
investig
kinet
drug
releas
result
macromolecular
prodrug
investig
use
intracellular
drug
deliveri
ribavirin
antiinflammatori
model
macrophag
result
identifi
polym
macromolecular
prodrug
devoid
blood
anticoagul
activ
strong
inhibitor
polymeras
efficaci
deliveri
vehicl
ribavirinthu
attract
develop
broadspectrum
antivir
agent
also
identifi
polym
benign
devoid
activ
test
thu
attract
stealth
materi
divers
biomed
applic
result
studi
would
import
advanc
biomed
engin
specif
regard
develop
antivir
therapi
drug
deliveri
techniqu
homopolym
differ
anion
monom
variat
anion
function
carboxyl
acid
sulfon
acid
phosphon
acid
phosphat
fig
obtain
revers
additionfragment
chain
transfer
raft
polymer
synthet
approach
synthesi
correspond
macromolecular
prodrug
chosen
proceed
via
copolymer
drug
contain
monom
correspond
carrier
polym
toward
end
rbv
contain
monom
design
compat
polymer
divers
comonom
acryl
methacryl
hydrophil
hydrophob
fig
synthesi
hydrophob
methacryl
monom
monom
fig
report
previou
public
acryl
counterpart
obtain
via
similar
protocol
minor
variat
design
consider
also
concern
polar
comonom
aspect
exert
limit
choic
solvent
polymer
polar
appli
anion
monom
vari
hydrophil
charact
phosphatesphosphon
well
pronounc
hydrophob
charact
ethylacryl
acid
propylacryl
acid
rbv
monom
therefor
design
mimic
polar
anion
comonom
use
silyl
protect
group
render
monom
hydrophob
use
deprotect
hydrophil
contain
monom
total
four
differ
rbv
prodrug
monom
appli
fig
allow
copolymer
perform
hydrophob
hydrophil
condit
either
acrylateacrylamid
methacrylatemethacrylamid
contain
monom
case
monom
structur
also
compris
disulfid
bond
intracellular
degrad
coupl
selfimmol
linker
drug
releas
due
variat
monom
type
monom
polar
uniqu
set
reaction
condit
necessari
copolymer
includ
choic
raft
agent
solvent
solvent
mixtur
reaction
time
initi
purif
procedur
tabl
full
detail
see
experiment
section
synthes
macromolecular
pro
drug
analyz
h
nmr
synthesi
assess
convers
two
monom
purifi
form
confirm
absenc
unreact
monom
polym
also
character
size
exclus
chromatographi
use
static
light
scatter
detector
determin
molar
mass
dispers
polym
sampl
tabl
acknowledg
co
polym
exhibit
variabl
degre
polymer
molar
mass
reason
analys
present
take
account
like
nonneglig
influenc
molar
mass
properti
polym
assum
polym
structur
factor
determin
polym
properti
wherea
molar
mass
secondari
import
inde
recent
public
antivir
activ
polym
reveal
clear
structureact
correl
regard
polym
function
wherea
clear
correl
polym
molar
mass
observ
blood
proanticoagul
known
side
effect
polyanion
upon
system
administr
inde
depend
structur
polyanion
may
exhibit
anticoagul
effect
wellknown
heparin
polysaccharid
approv
us
fda
specif
purpos
blood
anticoagul
polyanion
polyphosph
nucleic
acid
report
procoagul
interfer
blood
coagul
highli
desir
safeti
featur
inject
formul
identif
coagulationinert
polym
one
aim
studi
investig
activ
partial
thromboplastin
time
aptt
presenc
synthes
polyanion
plateletdeplet
plasma
healthi
donor
incub
polyanion
concentr
mgl
aptt
measur
fig
polysulfon
pvbza
mgl
enhanc
blood
coagul
time
valu
similarli
heparin
indic
strong
blood
anticoagul
also
observ
pvpa
doubl
aptt
valu
contrast
polyphosph
polyphosphon
papa
pmpa
paep
pmep
minor
influenc
blood
coagul
time
carboxyl
paa
pmaa
exhibit
notic
anticoagul
effect
contrast
peaa
ppaa
two
polym
enhanc
hydrophob
decreas
anion
charact
compar
paa
pmaa
higher
pka
effect
blood
coagul
time
mgl
taken
togeth
result
fig
reveal
six
test
polym
polyphosph
polyphosphon
peaa
ppaa
appear
inhibitori
activ
regard
blood
coagul
time
albumin
abund
protein
human
plasma
numer
physiolog
function
includ
mainten
tabl
polymer
condit
macromolecular
characterist
polyanion
macromolecular
prodrug
use
work
chemic
structur
detail
synthesi
rbv
contain
monom
see
fig
experiment
section
respect
chain
transfer
agent
cyanomethyl
dodecyl
trithiocarbon
cdtc
dodecylsulfanylthiocarbonyl
sulfanyl
pentano
acid
cdpa
cyanomethyl
methyl
phenyl
carbamodithio
cmpd
dodecylthiocarbonothioylthio
acid
dcma
phenylcarbonothioylthio
pentano
acid
cppa
polymer
initi
azobisisobutyronitril
aibn
valeronitril
acid
acva
n
numberaverag
molar
mass
secmal
size
exclus
chromatographi
multiangl
light
scatter
detect
dp
degre
polymer
valu
dndc
calcul
secmal
measur
assum
full
mass
recoveri
dp
valu
ppaa
ppaarbv
pvbza
mark
symbol
calcul
n
calc
experiment
condit
anion
homopolym
taken
ref
osmot
pressur
transport
hydrophob
solut
blood
protein
safeguard
bodi
physiolog
mechan
exist
ensur
albumin
degrad
retain
bodi
result
albumin
blood
resid
time
reach
phenomen
valu
week
albumin
bind
among
success
methodolog
biomedicin
extend
circul
time
solut
achiev
rang
drug
molecul
small
molecul
anticanc
drug
peptid
hormon
protein
recent
observ
synthet
polym
peaa
bind
albumin
afford
hepat
deposit
polym
albumin
bind
peaa
altogeth
surpris
protein
well
known
bind
hydrophob
solut
anion
solut
featur
emphas
structur
peaa
herein
aim
investig
albumin
bind
librari
anion
polym
without
conjug
ribavirin
albumin
sever
bind
site
notabl
socal
sudlow
sudlow
ii
site
bind
solut
site
interrog
use
fluoresc
probe
exhibit
sitespecif
bide
albumin
specif
dansyl
asparagin
sudlow
dansyl
sarcosin
sudlow
ii
fluoresc
probe
significantli
decreas
upon
displac
protein
globul
present
facil
methodolog
quantit
bind
albumin
polym
polym
mix
albumin
gl
concentr
protein
molar
equival
polym
albumin
immedi
observ
result
experi
fig
polym
differ
significantli
capac
interact
albumin
via
two
nomin
site
polyphosphon
polym
papa
brought
decreas
fluoresc
probe
indic
detect
polym
interact
albumin
papa
also
exhibit
anticoagul
activ
fig
togeth
data
suggest
papa
bloodsaf
carrier
divers
drug
deliveri
applic
albumin
bind
structur
similar
pmpa
well
phosphat
analogu
paep
pmep
also
pronounc
mole
excess
polym
albumin
probe
fluoresc
decreas
polysulfon
also
exhibit
minor
associ
albumin
afford
chang
fluoresc
sudlow
bind
probe
chang
fluoresc
sudlow
ii
probe
within
except
hydrophob
polym
styren
psvb
show
probe
displac
contrast
polycarboxyl
exhibit
strong
tendenc
bind
albumin
exhibit
highli
efficaci
probe
displac
bind
site
specif
probe
displac
sudlow
ii
site
case
paa
displac
probe
sudlow
ii
site
nearcomplet
indic
strong
bind
polym
incorpor
rbv
abrog
polym
bind
albumin
illustr
paa
bind
albumin
structureprogram
chang
macromolecul
addit
rbv
interfer
albumin
bind
pmaa
peaa
ppaa
also
exhibit
strong
probe
displac
capac
albeit
pronounc
paa
interestingli
unlik
paarbv
peaarbv
ppaarbv
strong
albumin
binder
albumin
bind
also
analyz
secmal
experi
confirm
differ
polym
capac
bind
albumin
highlight
chang
result
polymerprotein
associ
fig
elut
albumin
hardli
alter
upon
incub
pamp
polysulfon
taken
equimolar
concentr
albumin
minor
protein
aggreg
presenc
polym
observ
similar
protein
incub
papa
polyphosphon
polyphosph
well
pvsa
pspa
contrast
carboxyl
paa
pmaa
ppaa
pvbza
hydrophob
polysulfon
psvb
polymerprotein
interact
afford
strong
aggreg
format
high
molar
mass
product
mda
final
upon
incub
peaa
strong
sudlow
iii
probe
displac
polym
elut
albumin
shift
shorter
time
indic
increas
molar
mass
protein
would
expect
polymerprotein
adduct
minor
protein
aggreg
peaa
uniqu
polym
albumin
bind
without
notic
aggreg
observ
fig
polyanion
macromolecular
prodrug
exhibit
structuredepend
bind
albumin
via
sudlow
iii
site
interact
albumin
quantifi
use
fluoresc
probe
displac
assay
use
dansyl
asparagin
dansyl
sarcosin
probe
sudlow
sudlow
ii
site
respect
fluoresc
intens
probe
presenc
polyanion
normal
control
experi
probe
fluoresc
indic
probe
displac
probe
fluoresc
impli
quantit
displac
indic
strong
interact
polym
albumin
result
present
averag
three
independ
experi
sd
statist
signific
compar
control
sampl
evalu
via
oneway
anova
dunnett
multicomparison
posthoc
analysi
p
p
p
polym
studi
work
next
examin
macromolecular
prodrug
regard
kinet
drug
releas
rbv
conjug
design
revers
upon
scission
disulfid
linkag
specif
upon
cell
entri
intracellular
environ
character
rel
high
concentr
thiol
contain
tripeptid
glutathion
gsh
effect
trigger
degrad
disulfid
linkag
insid
cell
access
disulfid
within
structur
macromolecular
prodrug
vari
due
differ
size
side
group
function
polym
may
thu
exhibit
signific
differ
drug
releas
kinet
previous
investig
releas
rbv
drug
conjug
polym
via
linkag
use
studi
disulfid
trigger
pair
selfimmol
linker
via
hplc
herein
establish
h
nmrbase
method
quantifi
releas
rbv
illustr
fig
exampl
paparbv
macromolecular
prodrug
incub
presenc
gsh
disulfid
reshuffl
initi
spontan
cycliz
selfimmol
linker
ensu
releas
pristin
drug
ribavirin
fig
chemic
shift
ribavirin
proton
exhibit
welldefin
migrat
h
nmr
spectrum
time
signal
correspond
polymerbound
drug
decreas
wherea
free
rbv
increas
fig
b
integr
correspond
peak
provid
facil
mean
quantifi
rbv
bound
polym
releas
prodrug
releas
rbv
macromolecular
prodrug
fast
within
h
drug
releas
macromolecular
carrier
fig
kinet
profil
highli
advantag
significantli
faster
report
peptidebas
linker
drug
carrier
allow
rapid
drug
releas
upon
prodrug
cell
entri
note
data
fig
rather
similar
drug
releas
data
collect
prior
studi
via
hplc
serv
valid
establish
herein
nmrbase
approach
monitor
drug
releas
h
nmr
base
method
quantifi
drug
releas
appli
macromolecular
prodrug
base
polyanion
well
nonion
carrier
phpma
fig
within
h
observ
mp
exhibit
pronounc
releas
payload
signific
find
experi
hydrophob
polym
chain
pronounc
effect
kinet
drug
releas
contrast
correl
appear
exist
regard
charg
polym
anion
vs
charg
neutral
natur
neg
charg
polym
inde
structur
similar
phpma
pmaa
well
papa
paep
releas
ribavirin
quantit
within
h
reveal
differ
drug
releas
kinet
howev
rel
small
structur
chang
pmaa
peaa
peaa
ppaa
afford
signific
decreas
drug
releas
similarli
singl
methyl
group
variat
papa
pmpa
afford
pronounc
drop
amount
rbv
releas
within
h
like
explan
phenomenon
compact
less
hydrat
thu
less
access
polym
coil
increasingli
hydrophob
polym
hinder
gsh
initi
drug
releas
well
significantli
slower
releas
methacrylamid
base
phosphon
rel
acrylamid
base
phosphon
data
display
mean
standard
deviat
three
independ
experi
comparison
oneway
anova
analysi
varianc
perform
follow
tukey
post
hoc
test
p
therapeut
andor
side
effect
elicit
polyanion
pro
drug
investig
herein
would
like
manifest
due
interact
polym
macromolecul
protein
spectrum
polyanion
endogen
compound
rather
larg
competit
electrostat
interact
polymer
partner
highli
like
context
antivir
perform
polym
other
shown
polyanion
act
effici
inhibitor
polymeras
charg
neutral
polym
devoid
activ
point
anion
charg
polym
electrostat
interact
target
origin
observ
phenomenon
polym
synthes
work
analyz
inhibitor
two
type
polymeras
enzym
name
dnadepend
dna
polymeras
replicas
rnadepend
dna
polymeras
revers
transcriptas
fig
despit
similar
carri
multipl
anion
charg
polym
differ
markedli
abil
interfer
perform
polymeras
polyphosph
polyphosphon
nearli
devoid
inhibitori
activ
assay
regardless
polym
concentr
polymeras
remain
uninhibit
togeth
data
present
eg
papa
appear
uniqu
stealthlik
properti
nointerfer
coagul
assay
albumin
bind
competit
bind
polymeras
contrast
polycarboxyl
polysulfon
exhibit
dosedepend
polymeras
inhibit
rather
surpris
find
high
anion
charact
alon
make
polym
strong
inhibitor
homolog
row
carboxyl
peaa
exhibit
strongest
inhibitori
activ
complet
inhibit
revers
transcriptas
activ
mgl
polym
concentr
observ
echo
recent
find
appar
uniqu
pair
neg
charact
hydrophob
polym
backbon
render
peaa
efficaci
inhibitor
eg
hepat
c
viru
intracellular
replic
lead
polym
broadspectrum
antivir
activ
similar
observ
made
neg
charg
pvbza
also
character
pronounc
hydrophob
chain
due
aromat
ring
repeat
unit
polym
final
test
activ
polym
cell
cultur
evalu
polyanion
counterpart
conjug
rbv
inhibitor
inflamm
stimul
macrophag
previou
find
reveal
paarbv
inhibit
synthesi
inflammatori
marker
nitric
oxid
lipopolysaccharid
lp
stimul
macrophag
wherebi
polym
releas
drug
elicit
individu
antiinflammatori
activ
test
librari
polyanion
present
quantifi
inflammatori
respons
cell
incub
polym
rang
concentr
mgl
independ
metabol
activ
cell
indic
cell
viabil
measur
presto
blue
assay
experi
therefor
provid
inform
toxic
polym
macrophag
cell
cultur
antiinflammatori
activ
polym
none
test
polym
without
conjug
ribavirin
exhibit
notic
toxic
concentr
mgl
fig
overal
major
polym
also
devoid
activ
regard
inflamm
howev
sever
polym
compris
notabl
except
efficaci
inhibitor
inflamm
without
associ
toxic
cell
specif
among
polyanion
pmaa
peaa
pvbza
psvb
afford
signific
decreas
level
produc
macrophag
appar
unifi
structur
featur
four
polym
hydrophob
polyanion
use
work
decreas
inflammatori
respons
pvbza
psvb
observ
alreadi
mgl
make
polym
potent
test
polyanion
also
strike
fig
activ
polymeras
enzym
presenc
polyanion
mgl
reaction
mixtur
express
de
novo
synthes
nucleic
acid
rel
uninhibit
polymeras
reaction
statist
signific
compar
control
evalu
via
oneway
anova
dunnett
multicomparison
posthoc
analysi
p
p
p
two
polym
well
peaa
afford
highli
efficaci
decreas
synthesi
nearcomplet
suppress
inflamm
without
associ
toxic
cell
come
stark
contrast
rbv
base
treatment
could
afford
ca
reduct
level
subtox
concentr
drug
worthi
note
polyanion
typic
deem
restrict
cell
entri
howev
confoc
laser
scan
microscopi
evalu
polym
uptak
macrophag
reveal
pronounc
polymerassoci
fluoresc
insid
cell
fig
true
polym
polycarboxyl
polyphosph
polyphosphon
polysulfon
contrari
expect
cell
entri
appear
decis
observ
activ
polym
macromolecular
prodrug
rbv
synthes
meth
acryl
meth
acrylamid
type
anion
monom
thu
exclud
pvbza
pvpa
psvb
pvsa
pmaa
peaa
display
inher
structuredriven
effect
antiinflammatori
assay
case
therefor
possibl
discern
effect
elicit
polym
intracellularli
releas
rbv
like
polym
releas
drug
contribut
overal
antiinflammatori
respons
macrophag
pmaarbv
peaarbv
surpris
lead
assay
macromolecular
prodrug
base
pmpa
pamp
case
statist
signific
antiinflammatori
effect
observ
concentr
mgl
effect
efficaci
minor
associ
toxic
probe
mechan
activ
polym
assay
investig
potenti
antagon
polyanion
lp
inde
latter
anion
compon
compet
polyanion
interact
receptor
inconceiv
furthermor
prior
report
suggest
sulfat
polyaromat
suramin
antagon
lp
investig
exampl
peaa
lp
stimul
macrophag
perform
use
increas
concentr
lp
presenc
absenc
fix
concentr
polym
fig
assay
antagon
receptor
absenc
intracellular
effect
would
manifest
shift
potenc
lp
without
chang
efficaci
turn
intracellular
effect
absenc
receptor
antagon
would
mean
decreas
efficaci
inflammatori
respons
chang
potenc
lp
experiment
data
suggest
effect
like
observ
fig
peaa
exert
activ
receptor
antagon
intracellular
effect
inde
polym
afford
statist
signific
decreas
inflamm
also
chang
albeit
minor
one
ic
valu
lp
regard
stimul
macrophag
vs
mgl
presenc
peaa
result
studi
provid
comprehens
view
polyanion
backbon
macromolecular
broadspectrum
antivir
therapeut
togeth
result
screen
polyanion
inher
antivir
activ
present
data
provid
suggest
view
util
polyanion
macromolecular
prodrug
ribavirin
antivir
agent
summar
tabl
first
wish
evalu
valid
assumpt
tabl
mask
skew
observ
effect
lead
fals
neg
misinterpret
data
furthermor
termin
group
aris
differ
raft
agent
use
studi
produc
polym
may
also
consider
chang
polym
properti
regard
latter
point
note
hand
macromolecular
prodrug
rbv
prior
remov
cleavabl
endgroup
reveal
differ
antiinflammatori
activ
work
accommod
synthet
divers
polym
use
five
differ
raft
agent
tabl
see
correl
polym
activ
tabl
raft
agent
use
polym
synthesi
similarli
experiment
result
present
work
appear
show
correl
polym
molar
mass
blood
anticoagul
effect
polym
fig
show
strong
depend
natur
polym
charg
function
sulfon
carboxyl
phosphat
phosphon
n
dp
albumin
bind
result
probe
displac
result
fig
illustr
polycarboxyl
strong
albumin
binder
despit
variat
molar
mass
phosphatecontain
polyanion
weak
binder
even
highest
molar
mass
papa
drug
releas
kinet
macromolecular
prodrug
fig
show
statist
signific
correl
polym
hydrophob
polym
dp
polym
activ
rbv
deliveri
character
lowest
highest
dp
fact
lowest
highest
dp
polym
effect
screen
suggest
polym
structur
number
repeat
unit
structur
decis
util
polym
carrier
conjug
drug
without
doubt
exampl
strong
pronounc
effect
molar
mass
biomed
properti
polym
numer
import
factor
overlook
prior
work
regard
deliveri
rbv
found
high
molar
mass
restrict
polym
cell
entri
limit
observ
therapeut
effect
disregard
import
observ
data
studi
strongli
suggest
chemic
structur
polym
domin
factor
properti
least
experi
present
studi
wherea
polym
chain
length
secondari
import
first
import
conclus
regard
activ
polym
lead
polym
structur
inher
broadspectrum
antivir
activ
peaa
pvbza
psvb
appear
also
strong
anticoagul
strong
albumin
binder
fig
turn
weak
anticoagul
weak
albumin
binder
also
weak
inhibitor
viru
infect
conclus
may
altogeth
surpris
anticoagul
antivir
effect
like
due
interact
polym
proteinac
target
antivir
effectsglycoprotein
viru
capsid
result
impli
polyanion
macromolecular
pro
drug
well
suit
system
administr
exert
antivir
activ
circul
differ
perspect
three
lead
broadspectrum
antivir
activ
also
shown
work
inhibitori
activ
polymeras
possess
inher
activ
within
macrophag
absenc
cytotox
observ
intrigu
three
polym
may
therefor
inhibitori
virus
extraand
intracellularli
part
fulfil
desir
combin
antivir
effect
view
polym
becom
lead
candid
optim
design
microbicid
nonsystem
local
antivir
treatment
regret
design
ribavirin
mp
consid
work
meth
acryl
meth
acrylamid
current
investig
synthesi
mp
base
pvbza
psvb
next
step
optim
antivir
pro
drug
also
worthi
note
discoveri
famili
polyanion
devoid
inhibitori
activ
screen
perform
name
polyphosph
polyphosphon
polym
appear
weak
case
minim
interact
proteinac
target
assay
due
well
high
solubil
power
well
use
design
low
molar
mass
prodrug
inher
affin
bone
polym
highli
attract
carrier
divers
drug
deliveri
applic
specif
bone
target
result
averag
three
independ
experi
n
sd
lower
standard
error
bar
omit
clariti
statist
differ
inflamm
peaa
nonpeaa
treat
cell
compar
use
unpair
student
ttest
p
summari
experiment
result
studi
screen
inher
broadspectrum
antivir
activ
taken
ref
result
denot
polym
exhibit
nomin
properti
increasingli
pronounc
scale
polym
devoid
properti
effect
na
polym
analyz
test
antiinflammatori
activ
denot
effect
observ
minim
cytotox
treatment
chemic
purchas
sigma
aldrich
use
without
purif
unless
state
otherwis
ribavirin
purchas
apichemistri
h
nmr
c
nmr
record
bruker
biospin
gmbh
mhz
nmr
spectromet
multipl
indic
abbrevi
singlet
bs
broad
singlet
doublet
triplet
p
pentet
multiplet
hrm
record
bruker
maxi
impacttofm
electrospray
ioniz
esi
sizeexclus
chromatographi
sec
perform
use
system
compris
shimadzu
hplc
pump
shimadzu
refract
index
detector
wyatt
dawn
heleo
light
scatter
detector
along
pda
detector
equip
either
hemabio
linear
column
particl
length
mm
intern
diamet
mm
mzanalysentechnik
seri
ohpak
hq
shodex
column
dimens
mm
particl
size
b
mzgel
sdplu
linear
column
particl
length
mm
intern
diamet
mm
mzanalysentechnik
provid
effect
molecular
weight
rang
c
superos
increas
gl
ge
healthcar
pore
size
um
particl
size
um
inner
diamet
mm
length
mm
provid
effect
molecular
weight
rang
da
exclus
limit
da
solvent
use
either
pb
filter
filter
ppm
sodium
azid
ml
min
b
dmf
mm
libr
mlmin
c
pb
filter
filter
ppm
sodium
azid
mlmin
valu
dndc
use
molar
mass
calcul
establish
wyatt
malsastra
softwar
assum
full
mass
recoveri
plate
reader
experi
perform
black
optipl
enspir
multilabel
reader
perkin
monom
mg
mmol
equiv
dissolv
dri
thf
ml
n
atmospher
ml
mmol
equiv
ad
reaction
stir
room
temperatur
h
product
purifi
flash
column
chromatographi
meohdcm
residu
triethylamin
remov
dissolv
crude
mixtur
dcm
wash
nh
cl
twice
water
brine
organ
phase
dri
sodium
sulfat
filter
concentr
vacuo
yield
pure
product
tea
g
mmol
equiv
ad
cold
solut
disulfid
g
mmol
equiv
dcm
ml
n
atmospher
acryloyl
chlorid
g
mmol
equiv
ad
dropwis
maintain
temperatur
reaction
mixtur
heat
slowli
room
temperatur
stir
h
reaction
quench
wash
twice
nh
cl
brine
organ
phase
dri
sodium
sulfat
filter
concentr
vacuo
product
purifi
flash
column
chromatographi
pentaneetoac
yield
pure
product
light
yellow
liquid
g
solut
tertbutyldimethylsilyl
oxi
methyl
carbon
g
mmol
equiv
dri
dcm
ml
ad
cold
solut
disulfaneyl
ethyl
acryl
g
mmol
equiv
diea
g
mmol
equiv
dmap
g
mmol
equiv
dri
dcm
ml
n
atmospher
reaction
mixtur
stir
room
temperatur
h
result
convers
reaction
quench
wash
twice
nh
cl
brine
organ
phase
dri
magnesium
sulfat
filter
concentr
vacuo
product
purifi
flash
column
chromatographi
pentaneetaco
residu
pnitrophenol
remov
basic
alumina
column
chromatographi
etoacmeoh
yield
pure
product
colorless
solid
g
monom
synthes
follow
protocol
describ
situ
deprotect
perform
without
purif
monom
thu
crude
mixtur
obtain
accord
protocol
synthesi
monom
dissolv
thf
ml
n
atmospher
g
mmol
ad
reaction
stir
h
solvent
remov
vacuo
product
purifi
flash
column
chromatographi
dcmmeoh
residu
tea
remov
dissolv
product
chloroform
wash
twice
nh
cl
yield
pure
product
g
experiment
detail
synthes
ethylacryl
acid
propylacryl
acid
phosphat
phosphat
phosphon
acid
phosphon
acid
perform
accord
protocol
publish
previous
anion
homopolym
synthes
previous
describ
ref
dcma
mg
mmol
equiv
mg
mmol
equiv
dissolv
methanol
ml
monom
dissolv
dmf
ml
amp
dissolv
water
ml
ad
five
round
freezepumpthaw
perform
ampul
flame
seal
reaction
perform
h
reaction
mixtur
dilut
ph
nahco
na
co
buffer
purifi
dialysi
follow
lyophilis
obtain
pure
product
mg
recov
poli
phosphon
acidcorbv
phosphon
acid
g
mmol
equiv
dissolv
acet
buffer
ml
monom
g
mmol
equiv
dissolv
meoh
ml
ad
togeth
cdpa
mmol
equiv
acva
mmol
equiv
stock
solut
methanol
ml
ad
give
slightli
unclear
solut
five
round
freezepumpthaw
perform
ampul
flame
seal
reaction
perform
h
reaction
mixtur
dilut
ph
nahco
na
co
buffer
purifi
dialysi
follow
lyophilis
obtain
pure
product
mg
monom
mmol
equiv
cdpa
g
mmol
equiv
mmol
equiv
dissolv
methanol
ml
ad
acid
g
mmol
equiv
dissolv
water
ml
six
round
freez
pump
thaw
perform
ampul
flame
seal
reaction
perform
h
reaction
mixtur
dilut
ph
nahco
na
co
buffer
purifi
dialysi
obtain
pure
product
upon
lyophilis
cdpa
g
mmol
equiv
g
mmol
equiv
monom
mg
mmol
equiv
dissolv
methanol
ml
ad
phosphat
mg
mmol
equiv
dissolv
water
ml
mixtur
slightli
unclear
five
round
freez
pump
thaw
perform
ampul
flame
seal
reaction
perform
h
small
amount
precipit
observ
upon
reaction
mixtur
chang
notabl
viscos
reaction
mixtur
dilut
ph
nahco
na
co
buffer
purifi
dialysi
second
dialysi
perform
ethanolwat
yield
pure
product
lyophil
monom
mmol
equiv
cdpa
g
mmol
equiv
mmol
equiv
dissolv
methanol
ml
ad
phosphat
g
mmol
equiv
dissolv
water
ml
six
round
freez
pump
thaw
perform
ampul
flame
seal
reaction
perform
h
reaction
mixtur
dilut
ph
nahco
na
co
buffer
purifi
dialysi
second
dialysi
perform
ethanol
water
yield
pure
product
upon
lyophil
competit
assay
perform
plate
fluoresc
analyz
excit
wavelength
nm
emiss
wavelength
nm
plate
reader
polym
predissolv
minim
amount
dmso
dilut
pb
ph
stock
solut
human
serum
albumin
hsa
fluoresc
probe
dansyl
asparaginedansyl
sarcosin
prepar
pb
ph
compon
mix
pb
ad
obtain
total
volum
well
follow
concentr
hsa
dansyl
sarcosin
dansyl
asparagin
polym
correspond
equival
compar
albumin
upon
mix
plate
incub
h
allow
system
equilibr
data
repres
three
independ
experi
includ
three
technic
replic
polym
albumin
gl
dissolv
pb
ppm
nan
equimolar
amount
sampl
incub
h
room
temperatur
directli
inject
secmal
system
equip
biocolumn
use
pb
eluent
result
analyz
use
wyatt
softwar
astra
sampl
albumin
polym
ad
use
refer
order
compar
albumin
peak
regard
determin
molecular
weight
elut
time
observ
ribavirin
contain
polym
predissolv
minim
amount
ddmso
necessari
dilut
pb
ph
prepar
glutathion
gsh
also
dissolv
pb
ph
prepar
aliquot
polym
solut
mix
aliquot
gsh
solut
obtain
ml
sampl
contain
gl
polym
mm
gsh
sampl
incub
describ
time
upon
ellmann
reagent
ad
equimolar
amount
compar
gsh
quench
reaction
quench
sampl
analyz
h
nmr
spectroscopi
describ
main
text
time
point
measur
repeat
least
three
time
polym
raw
macrophag
cell
line
test
neg
mycoplasma
use
determin
antiinflammatori
activ
polyanion
cell
seed
flatbottom
plate
initi
densiti
cell
per
well
media
high
glucos
dmem
stabl
lglutamin
without
phenol
red
gibco
supplement
fb
penicillinstreptomycin
three
hour
cell
seed
polym
ad
indic
concentr
media
incub
cell
h
h
media
remov
cell
wash
pb
subsequ
cell
stimul
lp
sigma
h
level
nitric
oxid
quantifi
via
griess
assay
briefli
cell
supernat
mix
sulfanil
acid
gl
phosphor
acid
min
incub
dihydrochlorid
gl
ad
absorb
nm
measur
use
plate
reader
bmg
labtech
ortenberg
germani
level
nitrit
quantifi
sodium
nitrit
standard
curv
normal
neg
control
lpsstimul
cell
cell
viabil
measur
use
prestoblu
viabil
reagent
invitrogen
briefli
cell
incub
medium
contain
volum
prestoblu
reagent
h
incub
time
fluoresc
nmexperiment
wavelength
nmrefer
wavelength
measur
plate
reader
bmg
labtech
ortenberg
germani
cell
viabil
normal
viabil
cell
incub
pure
media
blood
obtain
healthi
donor
collect
sodium
citrat
tube
platelet
poor
plasma
ppp
obtain
centrifug
blood
min
polym
dissolv
pb
buffer
contain
dmso
polym
solut
mix
ppp
volum
volum
ratio
result
final
polym
concentr
mgl
prothrombin
time
measur
use
mrx
owren
pt
reagent
medirox
ghi
activ
partial
thromboplastin
time
measur
use
dade
actin
fs
siemen
measur
perform
sysmex
pb
pb
dmso
use
neg
control
heparin
sigma
use
posit
control
analyz
inhibitori
effect
polym
dnadna
polymeras
activ
quantiti
pcr
qpcr
reaction
perform
use
power
sybr
green
pcr
master
mix
life
technolog
accord
protocol
provid
manufactur
one
sampl
green
pcr
master
mix
mix
forward
revers
primer
ng
plasmid
nibsc
programm
eva
centr
aid
reagent
refer
number
polym
dilut
pb
desir
concentr
primer
complementari
ltr
upstream
element
gag
program
use
min
follow
cycl
last
cycl
melt
curv
made
level
inhibit
taq
polymeras
calcul
compar
posit
control
without
polym
enzym
activ
influenc
polym
activ
revers
transcriptas
determin
use
enzchek
revers
transcriptas
assay
kit
life
technolog
reaction
mixtur
prepar
accord
protocol
provid
manufactur
subsequ
polym
dilut
pb
ad
given
concentr
u
mulv
revers
transcriptas
life
technolog
cat
nr
reaction
perform
h
nucleic
acid
stain
picogreen
dye
fluoresc
measur
plate
reader
bmg
labtech
ortenberg
germani
cellular
uptak
polyanion
macrophag
evalu
confoc
laser
scan
microscopi
coverslip
thermofish
scientif
place
well
plate
coat
polyllysin
water
sigmaaldrich
h
wash
twice
pb
ph
gibco
raw
cell
mycoplasma
neg
seed
coverslip
plate
media
high
glucos
dmem
stabl
lglutamin
gibco
supplement
fb
penicillinstreptomycin
h
seed
media
remov
well
mgl
fluoresc
label
polyanion
dilut
media
ad
well
h
addit
polyanion
cell
coverslip
process
confoc
microscopi
coverslip
wash
twice
pb
fix
paraformaldehyd
pb
min
rt
follow
wash
twice
pb
coverslip
stain
dapi
pb
min
dapi
remov
wash
twice
pb
cell
membran
stain
concanavalin
conjug
alexa
lifetechnolog
min
rt
follow
stain
step
coverslip
wash
twice
pb
transfer
cell
face
microscopi
slide
vwr
cell
submerg
diamond
antifad
mountant
thermofish
scientif
slide
visualis
use
zeiss
confoc
oil
dic
object
use
excit
line
nm
dapi
nm
fitc
nm
alexa
spectral
overlap
collect
emiss
